# OnCo record gallbladder-cancer-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/gallbladder-cancer-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "gallbladder-cancer-roadmap" ;
  schema:name "Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials"@en ;
  schema:alternateName "Gallbladder carcinoma roadmap"@en, "Biliary tract cancer roadmap (gallbladder)"@en ;
  schema:description "Gallbladder cancer is usually found by accident when a gallbladder is removed for stones, and for most of its history the only treatment was a bigger operation. This roadmap follows the disease from the first cholecystectomy in 1882, through staging by depth and the borrowed chemotherapy standards of 2010 and 2019, to immunotherapy and HER2 drugs, and lists the trial readouts to watch to 2030."@en ;
  schema:url <https://onco.cc/roadmaps/gallbladder-cancer-roadmap/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/8466463>, <https://europepmc.org/article/MED/782269>, <https://europepmc.org/article/MED/13205425>, <https://europepmc.org/article/MED/1247951>, <https://europepmc.org/article/MED/362580>, <https://europepmc.org/article/MED/17846848>, <https://europepmc.org/article/MED/20375404>, <https://europepmc.org/article/MED/24854451>, <https://europepmc.org/article/MED/28752469>, <https://europepmc.org/article/MED/30582640>, <https://europepmc.org/article/MED/33798493>, <https://europepmc.org/article/MED/37276871>, <https://europepmc.org/article/MED/40381735>, <https://europepmc.org/article/MED/36372281>, <https://europepmc.org/article/MED/34918177>, <https://europepmc.org/article/MED/40052976>, <https://europepmc.org/article/MED/42013358>, <https://clinicaltrials.gov/study/NCT02170090>, <https://clinicaltrials.gov/study/NCT04559139>, <https://clinicaltrials.gov/study/NCT03673072>, <https://clinicaltrials.gov/study/NCT02867865>, <https://clinicaltrials.gov/study/NCT06109779>, <https://clinicaltrials.gov/study/NCT06282575>, <https://clinicaltrials.gov/study/NCT03875235>, <https://clinicaltrials.gov/study/NCT04482309> ;
  onco:tag "gallbladder", "biliary", "roadmap" ;
  onco:related <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/roadmaps/chemotherapy-roadmap/>, <https://onco.cc/roadmaps/surgery-roadmap/>, <https://onco.cc/roadmaps/prevention-roadmap/>, <https://onco.cc/roadmaps/early-detection-roadmap/>, <https://onco.cc/roadmaps/ctdna-tests/>, <https://onco.cc/pairings/gemcis-plus-io-btc/>, <https://onco.cc/ideas/idea-gbc-report-gallbladder-separately-in-biliary-trials/>, <https://onco.cc/ideas/idea-gbc-national-incidental-cancer-pathway/>, <https://onco.cc/ideas/idea-gbc-t1b-simple-cholecystectomy-prospective-study/>, <https://onco.cc/ideas/idea-gbc-t2a-spare-liver-resection-trial/>, <https://onco.cc/ideas/idea-gbc-reflex-her2-testing-advanced-biliary/>, <https://onco.cc/ideas/idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions/>, <https://onco.cc/ideas/idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated/>, <https://onco.cc/ideas/idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance/>, <https://onco.cc/ideas/idea-gbc-ctdna-residual-disease-guided-adjuvant-trial/>, <https://onco.cc/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/>, <https://onco.cc/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/>, <https://onco.cc/ideas/idea-gbc-burden-to-funding-audit-and-dedicated-call/> ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/> ;
  onco:sections <https://onco.cc/fronts/surgery/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/prevention/>, <https://onco.cc/fronts/early-detection/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/ultrasound/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/signatera/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/zymeworks/> ;
  onco:institutions <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/the-christie/>, <https://onco.cc/institutions/tata-memorial/>, <https://onco.cc/institutions/ecog-acrin/>, <https://onco.cc/institutions/swog/>, <https://onco.cc/institutions/esmo/>, <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/cancers/incidental-gallbladder-cancer/>, <https://onco.cc/terms/radical-cholecystectomy/>, <https://onco.cc/terms/t2a-versus-t2b/>, <https://onco.cc/terms/gallbladder-polyp/>, <https://onco.cc/terms/prophylactic-cholecystectomy/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/her2-positive/> ;
  onco:trials <https://onco.cc/trials/abc-02/>, <https://onco.cc/trials/bilcap/>, <https://onco.cc/trials/abc-06/>, <https://onco.cc/trials/topaz-1/>, <https://onco.cc/trials/keynote-966/>, <https://onco.cc/trials/herizon-btc-01/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/trials/nifty/>, <https://onco.cc/trials/naliricc/>, <https://onco.cc/trials/swog-s0809/>, <https://onco.cc/trials/opt-in/>, <https://onco.cc/trials/gain-igbc/>, <https://onco.cc/trials/polcagb/>, <https://onco.cc/trials/acticca-1/>, <https://onco.cc/trials/nct06109779/> ;
  onco:people <https://onco.cc/people/juan-valle/>, <https://onco.cc/people/john-primrose/>, <https://onco.cc/people/angela-lamarca/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-prevention-adoption/>, <https://onco.cc/bottlenecks/b-trial-enrolment/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-care-fragmentation/>, <https://onco.cc/bottlenecks/b-funding-allocation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-abc-02-gemcitabine-cisplatin-nejm-2010/>, <https://onco.cc/key-papers/paper-bilcap-lancet-oncol-2019/>, <https://onco.cc/key-papers/paper-topaz-1-nejm-evidence-2022/>, <https://onco.cc/key-papers/paper-keynote-966-lancet-2023/>, <https://onco.cc/key-papers/paper-harding-lancet-oncol/>, <https://onco.cc/key-papers/paper-destiny-pantumor02-jco-2024/>, <https://onco.cc/key-papers/paper-abc-06-folfox-second-line-lancet-oncol-2021/>, <https://onco.cc/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015/>, <https://onco.cc/key-papers/paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007/>, <https://onco.cc/key-papers/paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022/>, <https://onco.cc/key-papers/paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026/>, <https://onco.cc/key-papers/paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020/> .